Pfizer's dividend yield is a lofty 6.2%. That's well above the 1.1% yield offered by the S&P 500 index and the 1.7% yield of the average pharmaceutical stock. And the company recently provided ...

Revenues from Pfizer’s non-COVID products rose 6% operationally in 2025. Its recently launched and acquired products ...

Investing.com -- Barclays launched coverage of U.S. large-cap biopharmaceutical companies, arguing the sector could regain ...

Pfizer (NYSE: PFE) is the name behind one of the world's top-selling products: the coronavirus vaccine. It brought in more ...

Is Pfizer’s 6% dividend yield a rare value opportunity in 2026, or is Wall Street pricing in bigger risks ahead?

​Pfizer Inc. (NYSE:PFE) is among the Best Affordable Stocks Under $40 to Buy. On February 17, Pfizer Inc. (NYSE:PFE) ...

Johnson & Johnson is upgraded to Buy and Pfizer to Hold reflecting improved profitability outlooks post-Q4 2025 earnings.

PFE stock decreased 30.0% from a peak of $40.71 on January 23, 2020, to $28.49 on March 23, 2020, compared to a ...

Nektar Therapeutics sees its stock nearly double after announcing positive Phase IIb data for its lead pipeline candidate, ...

Pfizer Inc. delivered a 17% total return since early November, but fundamentals lag and valuation isn’t compelling. Read more on PFE stock here.

"Second Pfizer Braftovi regimen shows benefit in mCRC" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Pfizer (NYSE:PFE) leads in biopharmaceuticals and vaccines, with strong performance reflected in the S&P 500 index.